Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob A de Man

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
BMJ Open|March 3, 2018
Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data? <i>A retrospective cohort study</i>Nèwel Salet, Rolf H Bremmer, Marc A M T Verhagen, et al.
Journal of Surgical Oncology|August 13, 2015
Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinomaStef Levolger, Mark G van Vledder, Rahat Muslem, et al.
Journal of Hepatology|November 25, 2010
Management of hepatocellular adenoma during pregnancyJohanna E Noels, Susanna M van Aalten, Dirk J van der Windt, et al.
European Radiology Experimental|March 12, 2024
Non-contrast short MRI surveillance for HCC screening: the study protocol of the SMS-HCC prospective multicenter studyCéline van de Braak, François E J A Willemssen, Rob A de Man, et al.
Clinics and Research in Hepatology and Gastroenterology|April 8, 2015
Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The NetherlandsLydia G M van der Geest, Suzanne van Meer, Janina G H Schrier, et al.
JHEP Reports : Innovation in Hepatology|June 17, 2025
Corrigendum to 'B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis' [J Hepatol (2022) doi: 10.1016/j.jhepr.2022.100460]Maaike Biewenga, Sebastiaan Heidt, Manon Vergunst, et al.
JHEP Reports : Innovation in Hepatology|April 4, 2022
B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitisMaaike Biewenga, Sebastiaan Heidt, Manon Vergunst, et al.
European Journal of Gastroenterology & Hepatology|May 17, 2019
Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infectionsAafke A Duizendstra, Robert J de Knegt, Michiel G H Betjes, et al.
Journal of Viral Hepatitis|September 13, 2021
Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infectionHannah S J Choi, Milan J Sonneveld, Mina S Farag, et al.
Acta Histochemica|July 8, 2005
Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysisHerman van Dekken, Cees Verhoef, Josiane Wink, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
BMJ Open|March 3, 2018
Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data? <i>A retrospective cohort study</i>Nèwel Salet, Rolf H Bremmer, Marc A M T Verhagen, et al.
Journal of Surgical Oncology|August 13, 2015
Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinomaStef Levolger, Mark G van Vledder, Rahat Muslem, et al.
Journal of Hepatology|November 25, 2010
Management of hepatocellular adenoma during pregnancyJohanna E Noels, Susanna M van Aalten, Dirk J van der Windt, et al.
European Radiology Experimental|March 12, 2024
Non-contrast short MRI surveillance for HCC screening: the study protocol of the SMS-HCC prospective multicenter studyCéline van de Braak, François E J A Willemssen, Rob A de Man, et al.
Clinics and Research in Hepatology and Gastroenterology|April 8, 2015
Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The NetherlandsLydia G M van der Geest, Suzanne van Meer, Janina G H Schrier, et al.
JHEP Reports : Innovation in Hepatology|June 17, 2025
Corrigendum to 'B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis' [J Hepatol (2022) doi: 10.1016/j.jhepr.2022.100460]Maaike Biewenga, Sebastiaan Heidt, Manon Vergunst, et al.
JHEP Reports : Innovation in Hepatology|April 4, 2022
B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitisMaaike Biewenga, Sebastiaan Heidt, Manon Vergunst, et al.
European Journal of Gastroenterology & Hepatology|May 17, 2019
Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infectionsAafke A Duizendstra, Robert J de Knegt, Michiel G H Betjes, et al.
Journal of Viral Hepatitis|September 13, 2021
Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infectionHannah S J Choi, Milan J Sonneveld, Mina S Farag, et al.
Acta Histochemica|July 8, 2005
Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysisHerman van Dekken, Cees Verhoef, Josiane Wink, et al.
Pageof 4